<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481909</url>
  </required_header>
  <id_info>
    <org_study_id>SMART-2010-1</org_study_id>
    <nct_id>NCT01481909</nct_id>
  </id_info>
  <brief_title>Study on Mastocytosis for Rupatadine Treatment</brief_title>
  <acronym>SMART</acronym>
  <official_title>Study on Mastocytosis for Rupatadine Treatment An Exploratory Phase IV, Randomised, Double-blind, Placebo Controlled Crossover Study to Assess the Efficacy of 20 mg Rupatadine on the Treatment of</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcus Maurer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study title:&#xD;
&#xD;
      An exploratory, randomised, double-blind, placebo controlled crossover study to assess the&#xD;
      efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms.&#xD;
&#xD;
      Study code:&#xD;
&#xD;
      SMART-2010-1 Principal Investigator, Co-Investigator, sponsor, and study centre (acc. to § 40&#xD;
      Abs. 4 AMG) Dr. med. F. Siebenhaar, Prof. Dr. Med. M. Maurer, Allergie-Centrum-Charité,&#xD;
      Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1,&#xD;
      D-10117 Berlin Biometry and biostatistical analyses Division of Biostatistics and Clinical&#xD;
      Epidemiology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Monitoring&#xD;
      Coordination Centre for Clinical Studies (KKS), Charité - Universitätsmedizin Berlin,&#xD;
      Charitéplatz 1, D-10117 Berlin Clinical phase Phase II&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      Reduction of wheal and flare type skin reaction after standardised provocation testing&#xD;
      assessed by volumetric and thermographic measurements.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Improvement of additional related symptoms (e.g. pruritus) and subjective affliction as&#xD;
      assessed by symptom score, DLQI, Itchy-QoL and VAS.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      An exploratory, randomised, double-blind, placebo controlled crossover study&#xD;
&#xD;
      Type and number of patients:&#xD;
&#xD;
      Male and female patients (n = 30) with cutaneous mastocytosis and indolent systemic&#xD;
      mastocytosis with skin involvement&#xD;
&#xD;
      Main criteria for inclusion:&#xD;
&#xD;
      Mastocytosis patients aged 18-65 years, signed written consent, no systemic corticosteroid or&#xD;
      other immunosuppressive therapy, no permanent severe diseases Test product, dose and mode of&#xD;
      administration 20 mg Rupatadine or placebo before provocation testing, oral administration&#xD;
      (tablets)&#xD;
&#xD;
      Duration of treatment:&#xD;
&#xD;
      28 days (testing will be done at the day of last treatment)&#xD;
&#xD;
      Assessment of efficacy:&#xD;
&#xD;
        1. Assessment of wheal and flare development by planimetric analyses of digital&#xD;
           photographic, volumetric, and thermographic imaging (time lapse) before and after&#xD;
           treatment with study medication,&#xD;
&#xD;
        2. Additional assessment of symptoms,&#xD;
&#xD;
        3. Assessment of life quality&#xD;
&#xD;
      Main criteria of evaluation:&#xD;
&#xD;
      Efficacy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pruritus</measure>
    <time_frame>10 weeks</time_frame>
    <description>Reduction of pruritus and wheal and flare type skin reaction after standardised provocation testing as assessed by volumetric and thermographic measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionaire</measure>
    <time_frame>10 weeks</time_frame>
    <description>Improvement of additional disease related symptoms and subjective affliction as measured by physician and patient global assessments, DLQI, Itchy-QoL and QoL(i)MaP*.&#xD;
*not validated questionnaire for mastocytosis symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Mastocytosis</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rupafin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadin</intervention_name>
    <description>20 mg, 28 days over 60 days</description>
    <arm_group_label>Rupafin</arm_group_label>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Each tablet contains 10 mg RUP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic&#xD;
             mastocytosis with skin involvement and a positive Darier's Sign&#xD;
&#xD;
          2. Age between 18 and 65 years.&#xD;
&#xD;
          3. Female patients must be using a highly effective method of birth control (such as&#xD;
             implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence,&#xD;
             vasectomised partner), or they must be postmenopausal, surgically sterilised, or&#xD;
             hysterectomised.&#xD;
&#xD;
          4. Voluntarily signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of permanent severe diseases, especially those affecting the immune&#xD;
             system, except for mastocytosis&#xD;
&#xD;
          2. History or presence of epilepsy, significant neurological disorders, cerebrovascular&#xD;
             attacks or ischemia&#xD;
&#xD;
          3. History or presence of myocardial infarction or cardiac arrhythmia which requires drug&#xD;
             therapy, hyper-/hypokalemia, bradycardia &lt; 50bpm, QTc interval &gt; 440ms&#xD;
&#xD;
          4. Evidence of severe renal dysfunction (creatinine &gt; 1,5 x upper reference value)&#xD;
&#xD;
          5. Evidence of significant hepatic disease (liver enzymes &gt; 2 x upper reference value)&#xD;
&#xD;
          6. History of adverse reactions to RUP, or other ingredients of the IMP&#xD;
&#xD;
          7. Presence of active cancer which requires chemotherapy or radiation therapy&#xD;
&#xD;
          8. Aggressive systemic mastocytosis&#xD;
&#xD;
          9. History or presence of alcohol abuse or drug addiction&#xD;
&#xD;
         10. Participation in any clinical trial within 4 weeks prior to enrolment&#xD;
&#xD;
         11. Commitment to an institution in terms of § 40 Abs. 1 S. 3 Nr. 4 AMG&#xD;
&#xD;
         12. Intake of antihistamines or leukotriene antagonists within 7 days prior to the&#xD;
             beginning of the study&#xD;
&#xD;
         13. Intake of oral corticosteroids within 14 days prior to the beginning of the study&#xD;
&#xD;
         14. Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before&#xD;
             beginning of the study&#xD;
&#xD;
         15. Pregnancy or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Berlin Charitè</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Marcus Maurer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Assessment of wheal and flare development</keyword>
  <keyword>Assessment of life quality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

